HB 1463 would create a new state task force on diabetes management within the Department of Health to study whether Florida should establish a referral program that connects people diagnosed with diabetes to federally qualified health centers and other covered entities, regardless of insurance status. The task force would be appointed by November 1, 2025, meet by January 1, 2026, and report its findings and any recommended criteria by May 1, 2026. If the task force recommends the program, the State Surgeon General would generally be required to establish it by January 1, 2027, unless the Surgeon General instead pursues a federal Medicaid Section 1115 waiver or the Department of Health reports that federal law creates barriers to implementation.
The bill also directs the Department of Health to create and maintain a website, if the program is established, to collect patient information, identify appropriate federally qualified health centers or covered entities, and share referral information. Those centers would be required to make a good-faith effort to schedule an appointment within 30 days of receiving a referral. The bill authorizes rulemaking to implement these provisions and allows the task force to be reestablished later if additional criteria are needed.
In addition to the task force and referral program, HB 1463 expands pharmacy authority in emergency situations. It would allow pharmacists, under specified conditions, to prescribe and dispense up to a 30-day supply of insulin drugs, glucagon drugs, diabetes devices, and diabetic ketoacidosis devices when a patient has less than a 7-day supply and is at risk of significant harm. The bill limits what pharmacists may charge, requires notice to the original prescriber, and directs the Department of Health to notify pharmacists about the new requirements.
The bill would also change insurance coverage rules for diabetes care. It creates parallel provisions for health insurance policies, health maintenance contracts, and related coverage laws requiring coverage for diabetes laboratory and diagnostic testing, including hemoglobin A1c testing and retinopathy screening, when such services are otherwise covered. It caps cost-sharing at $35 for a 30-day supply of insulin, noninsulin, or glucagon drugs and at $100 for a 30-day supply of medically necessary diabetes and diabetic ketoacidosis devices, applying to policies and contracts issued, renewed, or amended on or after January 1, 2026.
Finally, the bill amends Florida’s prescription drug monitoring program so dispensers must report insulin drugs, glucagon drugs, diabetes devices, and diabetic ketoacidosis devices in the same manner as controlled substances. Overall, the bill is a broad diabetes-access measure affecting the Department of Health, pharmacists, insurers, health maintenance organizations, federally qualified health centers, and the state’s prescription monitoring system. The bill died in the House Health Professions & Programs Subcommittee, and the available record shows no recorded votes or committee transcript, suggesting no documented floor-level debate in the provided materials.
HB 1463 would create new duties in Florida Statutes chapter 385 for the Department of Health and the State Surgeon General, add emergency refill authority in s. 465.0275, impose coverage and cost-sharing limits in new sections of chapters 627 and 641, and expand reporting obligations under the prescription drug monitoring program in s. 893.055. It would directly affect pharmacists, insurers, HMOs, federally qualified health centers, covered entities, and patients with diabetes by changing access, referral, coverage, and reporting requirements.
The bill’s structure suggests a generally supportive policy approach toward improving diabetes access, affordability, and continuity of care, with multiple provisions aimed at reducing barriers to treatment and medication access. However, because the bill died in the Health Professions & Programs Subcommittee and there are no recorded votes or transcripts in the provided materials, there is no documented committee sentiment beyond the bill’s failure to advance.
The main potential points of contention are likely to have been the bill’s insurance mandates and cost-sharing caps, the requirement that pharmacists dispense emergency supplies under specified conditions, and the creation of a state referral program involving collection and sharing of patient information. The bill also raises possible concerns about administrative burden on the Department of Health, pharmacies, insurers, and federally qualified health centers, as well as federal-law and Medicaid-waiver issues acknowledged in the text itself. Supporters would likely emphasize access and affordability, while opponents may have focused on cost, regulatory expansion, and implementation complexity.